Tonix’s Second GPO Agreement for TONMYA Signals a Market Access Inflection Point for Fibromyalgia Coverage
Tonix Pharmaceuticals secured a second GPO agreement June 1, 2026, expanding TONMYA commercial coverage to ~52M U.S. lives—10 months...
Market Access
The Pricing Policy Mirage: Three Signals That Washington’s Drug Cost Crusade Is Reshaping Pharma Strategy Without Fixing Prices
Trump's executive orders and IRA negotiations promise relief, but branded drug prices rose 4.5% in 2024 and U.S. drugs...
Ovarian Cancer’s PARP Inhibitor Gold Rush Is Over — What Comes Next Will Separate the Winners From the Wreckage
PARP inhibitors reshaped ovarian cancer treatment, but with olaparib holding 38% market share and biomarker limits exposed, the next...
China’s Drug Machine Is Handing Western Pharma a Strategic Crisis Disguised as a Partnership Opportunity
China now drives first-in-class innovation, not just generics—and every Western pharma BD team underpricing that shift is building a...